Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy

Amber N. Clements, Andrea L. Casillas, Caitlyn E. Flores, Hope Liou, Rachel K. Toth, Shailender S. Chauhan, Kai Sutterby, Sachin Kumar Deshmukh, Sharon Wu, Joanne Xiu, Alex Farrell, Milan Radovich, Chadi Nabhan, Elisabeth I. Heath, Rana R. McKay, Noor Subah, Sara Centuori, Travis J. Wheeler, Anne E. Cress, Gregory C. Rogers, Justin E. Wilson, Alejandro Recio‐Boiles, Noel A. WarfelbioRxiv 2024 · DOI

Abstract

Immunotherapy has revolutionized the treatment of various malignancies, yet prostate cancer (PCa) remains largely resistant to immune checkpoint inhibitors (ICIs). This resistance is driven by an "immunologically cold" tumor microenvironment (TME) characterized by chronic inflammation and the presence of suppressive tumor-associated macrophages (TAMs). This study identifies PIM kinases as central regulators of inflammasome activation within TAMs. Clinical data from treatment-naïve patients reveal that high PIM1/2/3 expression correlates with an immunosuppressive TME and high levels of inflammatory cytokines (IL-1β and TNFα). By utilizing macrophage-specific PIM knockout models and pharmacological inhibition, we demonstrate that PIM inhibition reprograms TAMs, enhances the adaptive immune response, and synergizes with ICIs to significantly reduce tumor growth. These findings suggest that PIM inhibitors are a viable strategy to improve the efficacy of immunotherapy in prostate cancer.

Introduction

Prostate cancer is notoriously difficult to treat with standard immunotherapy. Unlike "hot" tumors that are heavily infiltrated by T cells, PCa creates a protective shield of chronic, "smoldering" inflammation. At the heart of this environment are tumor-associated macrophages (TAMs), which utilize protein complexes called inflammasomes to produce pro-inflammatory cytokines. While inflammation is often associated with immune activity, in the context of the TME, it frequently serves to suppress cytotoxic T-cell function and promote tumor progression. This research investigates whether PIM kinases—enzymes typically associated with cancer cell survival—act as master switches for this inflammatory machinery in macrophages.

Methodological Approach

The researchers employed a multi-faceted experimental design to bridge clinical observations with mechanistic insights:

  • Clinical Correlation: Transcriptomic and DNA sequencing data from a cohort of 44 metastatic hormone-sensitive PCa patients (Caris Life Sciences) and the TCGA PRAD dataset (n=498) were analyzed to link PIM levels with immune cell density.
  • Genetic and Pharmacological Models: The team generated "Triple Knockout" (TKO) bone marrow-derived macrophages lacking PIM1, 2, and 3. They also utilized PIM447, a pan-PIM inhibitor, in combination with anti-PD-1 therapy in syngeneic MyC-CaP mouse models.
  • Immune Profiling: To understand the shifting TME, the study used 17-color spectral flow cytometry and FlowSOM clustering to map immune cell populations with high resolution.

Mechanisms of PIM-Mediated Immunosuppression

The study reveals that PIM kinases drive inflammation by promoting the activation of NF-κB, a transcription factor that controls the expression of inflammasome components. In patients, high PIM expression was directly associated with increased macrophage markers (CD68, CD86, and MRC1) and elevated IL-1β.

Crucially, PIM inhibition does not merely deplete the macrophage population. Instead, it induces a functional reprogramming. Treated TAMs shift from a pro-tumor (M2) state toward an anti-tumor (M1) or "intermediate" phenotype. These reprogrammed macrophages are characterized by a massive increase in chemokines like CCL24, which help recruit and activate the "assassin" cells of the immune system: GranzymeB+ CD8+ T cells.

Therapeutic Synergy and Results

The most significant finding for clinical application is the synergy between PIM inhibitors and ICIs. In syngeneic models:

  • Monotherapy: PIM inhibitors or anti-PD-1 alone resulted in only a modest (~20%) reduction in tumor growth.
  • Combination Therapy: The dual treatment reduced tumor volume by approximately 80%.
  • Cellular Impact: Tumors treated with the combination therapy showed significantly higher levels of cell death (cleaved-caspase 3) and a robust infiltration of activated cytotoxic T cells.

Conclusion and Future Directions

This study provides a compelling rationale for targeting PIM kinases to overcome immunotherapy resistance in prostate cancer. By silencing the macrophage-driven inflammasome, PIM inhibitors transform the TME from a repressive environment into one that supports active anti-tumor immunity.

Future research will need to address the specific roles of PIM isoforms, particularly PIM2, which appears to have a unique influence on T-cell interferon-gamma (IFNγ) levels. Additionally, while the "intermediate" macrophage phenotype observed after treatment is highly effective at reducing tumor burden in mice, its long-term stability in the complex human TME requires further investigation through clinical trials.

Summary updated

Abstract

Immunotherapy has changed the treatment paradigm for many types of cancer, but immune checkpoint inhibitors (ICIs) have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment (TME) and is associated with poor response to ICIs. The primary source of inflammatory cytokine production is the inflammasome. Here, we identify PIM kinases as important regulators of inflammasome activation in tumor associated macrophages (TAMs). Analysis of clinical data from a cohort of treatment naïve, hormone responsive PCa patients revealed that tumors from patients with high PIM1/2/3 display an immunosuppressive TME characterized by high inflammation (IL-1β and TNFα) and a high density of repressive immune cells, most notably TAMs. Strikingly, macrophage-specific knockout of PIM reduced tumor growth in syngeneic models of prostate cancer. Transcriptional analyses indicate that eliminating PIM from macrophages enhanced the adaptive immune response and increased cytotoxic immune cells. Combined treatment with PIM inhibitors and ICIs synergistically reduced tumor growth. Immune profiling revealed that PIM inhibitors sensitized PCa tumors to ICIs by increasing tumor suppressive TAMs and increasing the activation of cytotoxic T cells. Collectively, our data implicate macrophage PIM as a driver of inflammation that limits the potency of ICIs and provides preclinical evidence that PIM inhibitors are an effective strategy to improve the efficacy of immunotherapy in prostate cancer.
BibTeX
@misc{clements2024inhibition,
  author = {Amber N. Clements and Andrea L. Casillas and Caitlyn E. Flores and Hope Liou and Rachel K. Toth and Shailender S. Chauhan and Kai Sutterby and Sachin Kumar Deshmukh and Sharon Wu and Joanne Xiu and Alex Farrell and Milan Radovich and Chadi Nabhan and Elisabeth I. Heath and Rana R. McKay and Noor Subah and Sara Centuori and Travis J. Wheeler and Anne E. Cress and Gregory C. Rogers and Justin E. Wilson and Alejandro Recio‐Boiles and Noel A. Warfel},
  title = {{Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy}},
  year = {2024},
  doi = {10.1101/2024.10.21.618756},
  howpublished = {bioRxiv},
}
Figure